Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations. Attention will be give...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 82; no. 1; pp. 161 - 201
Main Authors Menter, Alan, Cordoro, Kelly M., Davis, Dawn M.R., Kroshinsky, Daniela, Paller, Amy S., Armstrong, April W., Connor, Cody, Elewski, Boni E., Gelfand, Joel M., Gordon, Kenneth B., Gottlieb, Alice B., Kaplan, Daniel H., Kavanaugh, Arthur, Kiselica, Matthew, Kivelevitch, Dario, Korman, Neil J., Lebwohl, Mark, Leonardi, Craig L., Lichten, Jason, Lim, Henry W., Mehta, Nehal N., Parra, Sylvia L., Pathy, Arun L., Farley Prater, Elizabeth A., Rupani, Reena N., Siegel, Michael, Stoff, Benjamin, Strober, Bruce E., Wong, Emily B., Wu, Jashin J., Hariharan, Vidhya, Elmets, Craig A.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2020
Subjects
clinical guidelines for psoriasis
comorbidities
dermatology
guidelines
pediatric
pediatric psoriasis
psoriasis
psoriasis guidelines
skin disease
UVB
UVA
FDA
NAFLD
PPD
PASI 75
TNF
pediatric
BSA
LDL
PUVA
pediatric psoriasis
guidelines
BMI
PSA
UV
GI
PASI
IL
OR
AAD
AOR
CI
skin disease
clinical guidelines for psoriasis
aHR
ICD
QOL
AAP
dermatology
CDLQI
comorbidities
NB
psoriasis
psoriasis guidelines
HPA
TCI
Online AccessGet full text

Cover

More Information
Summary:Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations. Attention will be given to pediatric patients with psoriasis, recognizing the unique physiology, pharmacokinetics, and patient-parent-provider interactions of patients younger than 18 years old. The topics reviewed here mirror those discussed in the adult guideline sections, excluding those topics that are irrelevant to, or lack sufficient information for, pediatric patients.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2019.08.049